Category: Biostatistics, Evidence Synthesis and Informatics
Professor Jonathan Sterne, Deputy Director of the National Institute for Health Research Bristol Biomedical Research ...
7-9 July 2021 Mendelian randomization: harnessing the power of population diversity and family relatedness Hosted ...
Bristol researchers to collaborate on national study to understand long COVID
What is long COVID and how can diagnosis be improved? ...
Genetic study of proteins is a breakthrough in drug development for complex diseases
An innovative genetic study of blood protein levels, led by ...
Analysis of seven trials finds that corticosteroids reduce risk of death by 20 per cent in critically ill COVID-19 patients
Corticosteroids reduce the risk of death among critically ill COVID-19 ...
Handgrip strength shown to identify people at high risk of type 2 diabetes
Findings demonstrate handgrip strength could be a cost-effective early screening ...
Implant choice more important than surgeon skill for hip replacement success
A study analysing over 650,000 hip replacement patients across England ...
Shoulder replacements benefit most patients for more than 10 years, study shows
More than 90 per cent of shoulder replacement implants last ...
Event: Cancer Research UK online project launch and networking session
22 September 2020. 9.45am – 12.30pm. Around 60,000 poeple in the UK are living with ...
Understanding the deadly link between COVID-19 and cardiovascular disease
Deborah Lawlor, Professor of Epidemiology at the University of Bristol and the NIHR Bristol BRC, ...
New Better Care South-West Partnership will join up data to improve and integrate care
A new partnership led by the University of Bristol that will join up data and ...
Study shows heavy smoking can have a damaging effect on facial ageing
Heavy smoking may have a causal effect on facial ageing, according to new research led ...
Dislocation following hip replacements has declined over time and has modifiable risk factors
Dislocation following primary total hip replacements has declined over time, and has a number of ...
Risk of bias in evidence underpinning approval of new cancer drugs raises questions
Around half of trials that supported new cancer drug approvals in Europe between 2014 and ...